CA125、CA72-4与CEA检测在卵巢肿瘤早期诊断中的临床价值

Clinical Value of CA125,CA72-4 and CEA Detection in Early Diagnosis of Ovarian Cancer

联合检测血清CA125、CA72-4与CEA水平对卵巢癌早期诊断的价值。对112例卵巢癌患者,185例卵巢良性肿瘤患者及对照组100名健康妇女,应用电化学发光免疫法测定血清CA125、CA72-4与CEA水平,然后进行统计分析。结果表明:健康妇女组和卵巢肿瘤组比较,卵巢癌组患者血清CA125、CA72-4与CEA水平及阳性率明显升高(P<0.01),三项标志物的阳性率分别为86.61%,67.86%,49.11%,三项联合检测阳性率为91.96%。血清CA125、CA72-4与CEA联检可以提高卵巢癌早期诊断的阳性率,对卵巢肿瘤的良恶性辅助诊断及鉴别诊断具有一定应用价值。

To explore the clinical values of combined detection of serum CA125,CA72-4 and CEA levels in the early diagnosis of ovarian cancer,the serum CA125,CA72-4 and CEA levels in 112 patients with ovarian cancer,185 patients with benign ovarian tumor and 100 healthy women controls were measured by electrochemical luminescence immunoassay（ECLIA）.The results showed that serum CA125,CA72-4 and CEA levels and positive rate in patients with ovarian cancer were significantly higher that of in patients with benign ovarian tumor and healthy controls（P〈0.01）.The positive rates of CA125,CA72-4 and CEA in patients with ovarian cancer were 86.61%,67.86% and 49.11%,respectively.The positive rate of three markers combined detection was 91.96%.The combined detection of the three markers may increase the positive rate in the early diagnosis of ovarian cancer,and help to differentiate the benign and malignant ovarian tumor.